V Autologous Bone Marrow Transplantation_2.pdf - Blog Science ...

More documents

Recommendations

Info

18 Session 1: Acute Myelogenous Leukemia - CR1 TABLES 1. 2. Increase of Leukemic Cell Kill in Bad Prognosis <strong>Marrow</strong> Harvest: 4HC in vitro treatment Recipient conditioning regimen: VP-16 CTX TBI 1500 mg/m 2 day -7 60 mg/kg days -6,-5 1.7 Gy bid days -3,-2,-1 FIGURE 1. Schema 1 TREATMENT OF AML PROTOCOL 82-86 INDUCTION: PRE-BKT INTENSIFICATION MAINTENANCE: HARVEST- AMSA-OAP HD ARA-C + AMSA AD-OAP AD-OAP AD-OAP HIGH DOSE THERAPY ^ + ^ MAINTENANCE: x 3 AMSA-OAP X 3
Double Intensification and ABMT FIGURE 2. Schema 2 TES CBV REGIMEN Total Dose day 1-4 day 1 day 1-3 FIGURE 3. Schema 3 TREATMENT DISTRIBUTION OF AML PATIENTS IN PROTOCOL 82-86 -ALLO BMT 6 •CBV-ABMT 18 •PROTOCOL VIOLATION 11 OR LOST TO F/U ENTERED 76 Cyclophosphamide 6 gr/m z BCNU 300 mg/m 2 VP-16 750 mg/m-2 BMT day 7 CR- 63 f-SEVERE ORGAN TOXICITY 4 •RELAPSE < 6 MOS 15 OR EARLY DEATH J-CONTROLS 9
Page 3: UBiv»rstt5ts-Krauk8Biiaas Eppendor
Page 6 and 7: Publication of these proceedings is
Page 8 and 9: B. Relapse JE Sanders, RHill, F App
Page 10 and 11: SESSION 3: CHRONIC MYELOGENOUS LEUK
Page 12 and 13: JP Eder and BA Teicher New Agents i
Page 14 and 15: AMCarella, P Codier, A Congiu, E Ga
Page 16 and 17: G Rosti, M Leoni, L Atbertazd, R Sa
Page 18 and 19: B Bostrom Can Maximal Dose Chemothe
Page 21: ACKNOWLEDGEMENTS The organizers tha
Page 24 and 25: 4 Session 1: Acute Myelogenous Leuk
Page 26 and 27: 6 Session 1: Acute Myelogenous Leuk
Page 29 and 30: 9 ABMT vs. Chemotherapy in Adults:
Page 31: 11 ABMT vs. Chemotherapy in Adults:
Page 34 and 35: 14 Session 1: Acute Myelogenous Leu
Page 43 and 44: 23 Role of Marrow Purging AUTOLOGOU
Page 45 and 46: Role of Marrow Purging 25 the leuke
Page 47 and 48: 27 Role of Marrow Purging The distr
Page 49 and 50: Role of Marrow Purging 29 REFERENCE
Page 51 and 52: 31 Role of Marrow Purging TABLE 2 A
Page 53 and 54: 33 Role of Marrow Purging FIGURE 3
Page 55 and 56: 35 Role of Marrow Purging FIGURE 7
Page 57 and 58: 37 ABMT: An Eastern Cooperative Onc
Page 59 and 60: 39 ABMT: An Eastern Cooperative Onc
Page 61: 41 ABMT: An Eastern Cooperative Onc
Page 88 and 89:
68 Session 1: Acute Myelogenous Leu
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 97 and 98:
77 BAVC Followed by Unpurged Marrow
Page 99 and 100:
79 BAVCFollowedby Unpurged Marrow I
Page 101 and 102:
81 ABMT with Unpurged Marrow AUTOLO
Page 103 and 104:
ABMT with Unpurged Marrow 83 Kaplan
Page 105 and 106:
85 ABMT with Unpurged Marrow 4. Gol
Page 107 and 108:
87 ABMT with Unpurged Marrow TABLE
Page 109:
89 ABMT with Unpurged Marrow FIGURE
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
100 Session 1: Acute Myelogenous Le
Page 122 and 123:
102 Session 1: Acute Myelogenous Le
Page 125 and 126:
105 ABMT with 4-HC Purged Marrow AU
Page 127 and 128:
107 ABMT with 4-HC Purged Marrow RE
Page 129 and 130:
109 ABMT with 4-HC Purged Marrow de
Page 131 and 132:
ABMT wüh 4-HC Purged Marrow TABLE
Page 133 and 134:
113 MonoclonalAntibody-PurgedABMT N
Page 135 and 136:
115 Monoclonal Antibody-PurgedABMT
Page 137 and 138:
117 MonoclonalAntibody-PurgedABMT (
Page 139 and 140:
119 MonoclonalAntibody-PurgedABMT R
Page 141 and 142:
121 MonoclonalAntïbody-PurgedABMT
Page 143 and 144:
123 Prognostic Factors for Hematolo
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
135 Cell Proliferation Studies with
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Cell Proliferation Studies with AST
Page 163 and 164:
Page 165 and 166:
145 Detection of Minimal Residual D
Page 167 and 168:
Page 169:
Page 172 and 173:
152 Session 2: Acute Lymphocytic Le
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 187 and 188:
167 ABMT: Report from Dana Farber C
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
177 Bone Marrow Purging BONE MARROW
Page 199 and 200:
179 Bone Marrow Purging intermediat
Page 201 and 202:
181 Bone Marrow Purging Clinical Ou
Page 203 and 204:
183 Bone Marrow Purging 12. Ramsay
Page 205 and 206:
185 Bone Marrow Purging TABLE 4 Sum
Page 207:
187 Bone Marrow Purging FIGURE 3 Di
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
202 Session 2: Acute Lymphocytic le
Page 225 and 226:
205 Chemotherapy Regimens and BMT I
Page 227 and 228:
207 Chemotherapy Regimens and BMT F
Page 229 and 230:
209 Chemotherapy Regimens and BMT F
Page 231 and 232:
211 Detection of Minimal Residual L
Page 233 and 234:
Page 235 and 236:
Page 237:
Page 240 and 241:
220 Session 3: Chronic Myelogenous
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 275 and 276:
255 Approaches to Prevent Relapse A
Page 277:
257 Approaches to Prevent Relapse F
Page 280 and 281:
260 Session 4: Supportive Care in g
Page 282 and 283:
262 Session 4: Supportive Care REFE
Page 284 and 285:
264 Session 4: Supportive Care TABL
Page 287 and 288:
267 Gram-Positive Septicemia CHARAC
Page 289 and 290:
269 Cram-Positive Septicemia treatm
Page 291 and 292:
271 Gram-Positive Septicemia Guiot
Page 293 and 294:
273 Ann' Fungal Therapy FLUCONAZOLE
Page 295 and 296:
275 Anti Fungal Therapy > different
Page 297 and 298:
277 Ana Fungal Therapy 19. Kroger H
Page 299:
279 Ana Fungal Therapy TABLE 2 INTE
Page 302 and 303:
282 Session 4: Supportive Care port
Page 304 and 305:
284 Session 4: Supportive Care infe
Page 306 and 307:
286 Session 4: Supportive Care REFE
Page 309 and 310:
289 COBE Spectra BONE MARROW CONCEN
Page 311 and 312:
291 COBE Spectra precursor assay (C
Page 313 and 314:
293 COBE Spectra TABLE 2 DEPLETION
Page 315:
295 COBE Spectra FIGURE 2 PROCEDURE
Page 318 and 319:
298 Session 4: Supportive Care The
Page 320 and 321:
300 Session 4: Supportive Care DISC
Page 322 and 323:
302 Session 4: Supportive Care 14.
Page 324 and 325:
304 Session 4: Supportive Care FIGU
Page 326 and 327:
306 Session 5: Breast Cancer - Meta
Page 328 and 329:
308 Session S: Breast Cancer - Meta
Page 330 and 331:
Page 333 and 334:
313 High Dose Therapy wäh ABMT HIG
Page 335 and 336:
315 High Dose Therapy with ABMT Thi
Page 337 and 338:
317 High Dose Therapy with ABMT for
Page 339 and 340:
319 High Dose Therapy with ABMT aut
Page 341:
321 High Dose Therapy with ABMT TAB
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
338 Session S: Breast Cancer - Meta
Page 360 and 361:
Page 363 and 364:
343 High Dose Therapy and ASC Rescu
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
353 High Dose Chemotherapy andBM HI
Page 375 and 376:
355 High Dose Chemotherapy and BMT
Page 377 and 378:
357 High Dose Chemotherapy and BMT
Page 379 and 380:
359 High Dose Cliemotherapy and BMT
Page 381:
361 High Dose Qiemotherapy and BM T
Page 384 and 385:
364 Session 5: Breast Cancer - Pre-
Page 386 and 387:
Page 388 and 389:
368 Session S: Breast Cancer - Pre-
Page 390 and 391:
Page 393 and 394:
373 New Agents in Chemotherap NEW A
Page 395 and 396:
375 New Agents in Chemotherapy of a
Page 397:
377 New Agents in Chemotherap 17. M
Page 400 and 401:
380 Session 6: Breast Cancer- Pre-M
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 413 and 414:
393 ABMT: Cooperative Pilot Study R
Page 415 and 416:
Page 417 and 418:
397 ABMT: Cooperative PUot Study Re
Page 419 and 420:
Page 421 and 422:
401 ÄBMT' Cooperative Pilot Study
Page 423 and 424:
Page 425 and 426:
405 Factors Affecting ABMT Results
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
411 Parma Pilot Study RELAPSE OF MA
Page 433 and 434:
413 Parma Pilot Study ABMT in the p
Page 435 and 436:
415 Parma Pilot Study Netherlands;
Page 437:
417 Parma Pilot Study FIGURE 1 PARM
Page 440 and 441:
420 Session 6: Lymphoma - Non-Hodgk
Page 442 and 443:
Page 444 and 445:
Page 447 and 448:
427 High Dose Etoposide and Melphal
Page 449 and 450:
Page 451:
Page 454 and 455:
Page 456 and 457:
436 Session 6: Lymphoma • Non-Hod
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
444 Session 6: Lymphoma • Non-Hod
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
454 Session 6: Lymphoma - Low Grade
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 485 and 486:
465 Ablative Therapy with ABMT ABLA
Page 487 and 488:
467 Ablative Therapy with ABMT RESU
Page 489 and 490:
469 Ablative Therapy with ABMT REFE
Page 491:
471 Ablative Therapy with ABMT TABL
Page 494 and 495:
474 Session 6: Non-Hodgkin's Lympho
Page 496 and 497:
Page 498 and 499:
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 507 and 508:
487 Studies with Sequential Transpl
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519:
Page 522 and 523:
502 Session 6: Lymphoma - Hodgkin's
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
518 Session 6: Lymphoma - Hodgkin*s
Page 540 and 541:
520 Session 6: Lymphoma - Hodgldn's
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 549 and 550:
529 ABMT and Cooperative Group Tria
Page 551 and 552:
531 ABMT and Cooperative Group Tria
Page 553 and 554:
533 ABUT and Cooperative Group Tria
Page 555 and 556:
535 ABMTand Cooperative Group Trial
Page 557:
537 ABMTandCooperative Group Trials
Page 560 and 561:
540 Session 6: Lymphoma PATIENTS AN
Page 562 and 563:
542 Session 6: Lymphoma RESULTS Lym
Page 564 and 565:
544 Session 6: Lymphoma with TBI; t
Page 566 and 567:
546 Session 6: Lymphoma TABLE 1 CON
Page 568 and 569:
548 Session 6: Lymphoma TABLE 5 PAT
Page 571 and 572:
551 Prospects for the Future AUTOGR
Page 573 and 574:
553 Prospects for the Future relaps
Page 575 and 576:
555 Prospects for the Future amelio
Page 577 and 578:
557 Prospects for the Future which
Page 579 and 580:
559 Prospects for the Future OVERVI
Page 581:
561 Prospects for the Future FIGURE
Page 584 and 585:
564 Session 6: Lymphoma - Myeloma M
Page 586 and 587:
566 Session 6: Lymphoma - Myeloma R
Page 588 and 589:
568 Session 6: Lymphoma - Myeloma 9
Page 590 and 591:
570 Session 6: Lymphoma - Myeloma F
Page 592 and 593:
572 Session 6: Lymphoma - Myeloma I
Page 594 and 595:
574 Session 6: Lymphoma - Myeloma w
Page 596 and 597:
576 Session 6: Lymphoma - Myeloma T
Page 598 and 599:
578 Session 6: Lymphoma - Myeloma T
Page 600 and 601:
580 Session 6: Lymphoma - Myeloma F
Page 602 and 603:
582 Session 6: Lymphoma - Myeloma A
Page 604 and 605:
584 Session 6: Lymphoma - Myeloma R
Page 607 and 608:
587 Neuroblastoma in Children OUTCO
Page 609 and 610:
589 Neuroblastoma in Children the 3
Page 611 and 612:
591 Neuroblastoma in Children Remis
Page 613 and 614:
593 Neuroblastoma in Children TABLE
Page 615 and 616:
595 Neuroblastoma in Children FIGUR
Page 617:
597 Neuroblastoma in Children FIGUR
Page 620 and 621:
600 Session 7: Solid Tumors and Eto
Page 622 and 623:
602 Session 7: Solid Tumors patient
Page 624 and 625:
604 Session 7: Solid Tumors state a
Page 626 and 627:
606 Session 7: Solid Tumors TABLE l
Page 628 and 629:
608 Session 7: Solid Tumors TABLE 2
Page 630 and 631:
Page 632 and 633:
612 Session 7: Solid Tumors was ass
Page 634 and 635:
614 Session 7: Solid Tumors microme
Page 636 and 637:
616 Session 7: Solid Tumors 13. Dim
Page 638 and 639:
Page 640 and 641:
620 Session 7: Solid Tumors Protoco
Page 642 and 643:
622 Session 7: Solid Tumors at diag
Page 644 and 645:
624 Session 7: Solid Tumors immunol
Page 646 and 647:
626 Session 7: Solid Tumors 3. Favr
Page 648 and 649:
628 Session 7: Solid Tumors TABLE I
Page 650 and 651:
630 Session 7: Solid Tumors TABLE m
Page 652 and 653:
632 Session 7: Solid Tumors childre
Page 654 and 655:
634 Session 7: Solid Tumors 6. Doug
Page 656 and 657:
636 Session 7: Solid Tumors FIGURE
Page 658 and 659:
638 Session 7: Solid Tumors BCNU wa
Page 660 and 661:
640 Session 7: Solid Tumors enhance
Page 662 and 663:
642 Session 7: Solid Tumors constan
Page 664 and 665:
Page 667 and 668:
647 Germ Cell Neoplasms DOSE INTENS
Page 669 and 670:
649 Germ &tt Neoplasms Indiana Univ
Page 671 and 672:
651 Germ CeUNeophsms Non-hematologi
Page 673:
653 Germ Cell Neoplasms Cancer. A S
Page 676 and 677:
656 Session 7: Solid Tumors Twelve
Page 678 and 679:
658 Session 7: Solid Tumors 5. Rich
Page 681 and 682:
661 Dose Intensive Therapy DOSE INT
Page 683 and 684:
663 Dose Intensive Therapy compared
Page 685 and 686:
665 Dose Intensive Therapy of thera
Page 687:
6 6 7 Dose Intensive Therapy TABLE
Page 690 and 691:
670 Session 7: Solid Tumors drugs c
Page 692 and 693:
672 Session 7: Solid Tumors cisplat
Page 694 and 695:
Page 697 and 698:
677 Conditioning Regimen for BMT BU
Page 699 and 700:
679 Conditioning Regimen for BMT To
Page 701 and 702:
681 Conditioning Regimen for BMT TA
Page 703 and 704:
683 Conditioning Regimen for BMT TA
Page 705:
685 Conditioning Regimen for BMT FI
Page 708 and 709:
688 Session 7: Solid Tumors consist
Page 710 and 711:
Page 713 and 714:
693 ABMT for Arthritis in Rats REMI
Page 715 and 716:
695 ABMT for Arthritis in Rats It i
Page 717:
697 ABMT for Arthritis in Rats FIGU
Page 720 and 721:
700 Session 8: New Avenues MATERIAL
Page 722 and 723:
702 Session 8: New Avenues positive
Page 724 and 725:
704 Session 8: New Avenues Previous
Page 726 and 727:
706 Session 8: New Avenues FIGURE 1
Page 728 and 729:
Page 730 and 731:
Page 732 and 733:
712 Session 8: New Avenues to thiou
Page 734 and 735:
714 Session 8: New Avenues analysis
Page 736 and 737:
716 Session 8: New Avenues Liver vo
Page 738 and 739:
718 Session 8: New Avenues TABLE 1
Page 740 and 741:
Page 742 and 743:
Page 744 and 745:
724 Session 8: New Avenues 1, dose-
Page 746 and 747:
726 Session 8: New Avenues Bone mar
Page 748 and 749:
728 Session 8: New Avenues ACKNOWLE
Page 750 and 751:
730 Session 8: New Avenues TABLE 1
Page 752 and 753:
Page 754 and 755:
734 Session 8: New Avenues transfer
Page 756 and 757:
736 Session 8: New Avenues a concen
Page 758 and 759:
738 Session 8: New Avenues Beta 5'U
Page 760 and 761:
740 Session 8: New Avenues 5. Stoec
Page 762 and 763:
Page 764 and 765:
Page 766 and 767:
Page 768 and 769:
Page 771 and 772:
751 Immunocytochemical Detection of
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
763 Immunotherapy: Post-ABMT Implic
Page 785 and 786:
Page 787 and 788:
Page 789 and 790:
Page 791 and 792:
771 Immunostimulation Post-ABMT IMM
Page 793 and 794:
773 Immunostimulation Post-ABMT are
Page 795 and 796:
775 Immunostimulation Post-ABMT cul
Page 797 and 798:
Ill Immunostimulation Post-ABMT 4.
Page 799 and 800:
779 Immunostimulation Post-ABMT FIG
Page 801 and 802:
781 ImmuMstimuIation Post-ABMT FIGU
Page 803 and 804:
783 Myelosuppressive Chemotherapy P
Page 805 and 806:
785 Myelosuppressive Chemotherapy P
Page 807 and 808:
787 Myelosuppressive Chemotherapy m
Page 809 and 810:
789 Myelosuppressive Chemotherapy T
Page 811 and 812:
791 Mobilization Techniques THE ROL
Page 813 and 814:
793 Mobilization Techniques Cell an
Page 815 and 816:
795 Mobilization Techniques 8. Bran
Page 817 and 818:
797 Mobilization Techniques FIGURE
Page 819:
799 Mobilization Techniques FIGURE
Page 822 and 823:
802 Session 9: Peripheral Stem Ceil
Page 824 and 825:
804 Session 9: Peripheral Stem Cell
Page 826 and 827:
806 Session 9: Peripheral Stern Cel
Page 828 and 829:
Page 830 and 831:
Page 832 and 833:
Page 834 and 835:
Page 836 and 837:
Page 838 and 839:
Page 840 and 841:
Page 843 and 844:
823 Acute Myeloid Leukemia PERIPHER
Page 845 and 846:
825 Acute Myeloid Leukemia leukemic
Page 847:
827 Acute Myeloid Leukemia after hi
Page 850 and 851:
Page 852 and 853:
Page 854 and 855:
Page 857 and 858:
837 Relapsed Lymphomas and Marrow M
Page 859 and 860:
839 Relapsed Lymphomas and Marrow M
Page 861 and 862:
841 High Risk Myeloma AUTOLOGOUS BL
Page 863 and 864:
843 High Risk Myeloma analysis for
Page 865 and 866:
845 High Risk Myeloma encountered,
Page 867 and 868:
847 High Risk Myeloma 10. Debecker
Page 869:
849 High Risk Myeloma TABLE 2 ABSCT
Page 872 and 873:
852 Session 10: Hematopoietic Growt
Page 874 and 875:
Page 876 and 877:
Page 878 and 879:
Page 880 and 881:
Page 882 and 883:
Page 884 and 885:
Page 886 and 887:
Page 888 and 889:
Page 890 and 891:
Page 892 and 893:
Page 894 and 895:
Page 896 and 897:
Page 898 and 899:
Page 901 and 902:
881 Role of Monocytes THE ROLE OF M
Page 903 and 904:
883 Role of Monocytes cells, always
Page 905 and 906:
885 Role of Monocytes CONCLUSION Th
Page 907 and 908:
887 Role of Monocytes TABLE 2 Proge
Page 909 and 910:
889 Role of Monocytes FIGURE 1 cont
Page 911 and 912:
891 Role of Monocytes FIGURE 3 Kine
Page 913 and 914:
893 InterleuIdn-2 Post-ABMT USE OF
Page 915 and 916:
895 Iníerkukin-2 Posí-ABMT Specif
Page 917 and 918:
897 Interleukin-2 Post-ABMT years;
Page 919 and 920:
899 Interieukin-2 Post-ABMT 19. Lau
Page 921 and 922:
901 Interleukin-2 Post-ABMT TABLE 2
Page 923 and 924:
903 Interleuldn-2 Post-ABMT FIGURE
Page 925 and 926:
905 Autotransplants: Present and Fu
Page 927 and 928:
Page 929:
Page 932 and 933:
912 Session 11: Concluding Remarks
Page 935 and 936:
CONTRIBUTORS Tauseef Ahmed, M.D., N
Page 937 and 938:
Anthony Elias, M.D., Dana Färber C
Page 939 and 940:
Per Ljungman, M.D., Ph.D., Departme
Page 941:
Yoichi Takaue, M.D., Department of
show all

V Autologous Bone Marrow Transplantation_2.pdf - Blog Science ...

Create successful ePaper yourself

Delete template?

Save as template?